RecruitingPhase 2NCT05549258
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
Studying Neuromyelitis Optica
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amgen
- Principal Investigator
- MDAmgen
- Intervention
- Inebilizumab(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 2-17 years · All sexes
- Timeline
- 2023 – 2027
Study locations (19)
- UCSD Altman Clinical and Translational Research Institute Building, La Jolla, California, United States
- Loma Linda University Children's Hospital - PIN, Loma Linda, California, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- Hospital de Pediatría S.A.M.I.C.- Prof. Dr. Juan P. Garrahan, Parque Patricios, Ciudad Autónoma de BuenosAires, Argentina
- Hospital Santa Izabel-Rua Floriano Peixoto 300, Salvador, Estado de Bahia, Brazil
- Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS), Porto Alegre/RS, Brazil
- CPQuali Pesquisa Clínica Sao Paulo, São Paulo, Brazil
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
- Hospital For Sick Children, Toronto, Ontario, Canada
- Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-Bicêtre, Val-de-Marne, France
- Erasmus MC Sophia Children's Hospital-Wytemaweg 80, Rotterdam, South Holland, Netherlands
- Uniwersyteckie Centrum Kliniczne w Gdansku - Smoluchowskiego 17, Gdansk, Poland
- Clinic for Neurology and Psychiatry for Children and Youth, Belgrade, Belgrade, Serbia
- Hospital Sant Joan de Deu - PIN, Espluges de Llobregat, Barcelona, Spain
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05549258 on ClinicalTrials.govOther trials for Neuromyelitis Optica
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT05909761Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During PregnancyAmgen
- RECRUITINGPHASE3NCT05199688A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)Hoffmann-La Roche
- RECRUITINGPHASE4NCT07420296Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum DisorderTianjin Medical University General Hospital
- RECRUITINGNCT06885957Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSDTongji Hospital
- RECRUITINGPHASE1NCT06620809The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum DisordersTongji Hospital
- RECRUITINGNANCT06865274Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNANCT06780709Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSDIcahn School of Medicine at Mount Sinai
- ACTIVE NOT RECRUITINGPHASE3NCT06724809Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDAlexion Pharmaceuticals, Inc.